MUFG Securities EMEA plc Raises Position in Pfizer (PFE)

MUFG Securities EMEA plc boosted its stake in shares of Pfizer (NYSE:PFE) by 293.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,150,000 shares of the biopharmaceutical company’s stock after acquiring an additional 2,350,000 shares during the quarter. Pfizer accounts for about 2.7% of MUFG Securities EMEA plc’s investment portfolio, making the stock its 3rd largest holding. MUFG Securities EMEA plc owned approximately 0.05% of Pfizer worth $114,093,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of the stock. Americafirst Capital Management LLC purchased a new stake in Pfizer in the 3rd quarter worth approximately $127,000. Delphi Private Advisors LLC lifted its holdings in Pfizer by 84.3% in the 4th quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 1,600 shares during the period. Lipe & Dalton lifted its holdings in Pfizer by 6.9% in the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 300 shares during the period. Legacy Advisors LLC purchased a new stake in Pfizer in the 3rd quarter worth approximately $164,000. Finally, Oak Point Wealth Management purchased a new stake in Pfizer in the 4th quarter worth approximately $165,000. Institutional investors own 71.19% of the company’s stock.

How to Become a New Pot Stock Millionaire

PFE has been the subject of several research analyst reports. Sanford C. Bernstein set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Tuesday, January 30th. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective for the company in a report on Wednesday, January 17th. Morgan Stanley set a $41.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Friday, January 5th. JPMorgan Chase reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, January 30th. Finally, Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price objective for the company in a report on Monday, January 8th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $39.20.

In related news, insider Mikael Dolsten sold 13,986 shares of the firm’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $35.85, for a total transaction of $501,398.10. Following the completion of the transaction, the insider now owns 120,884 shares of the company’s stock, valued at approximately $4,333,691.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $37.19, for a total value of $353,676.90. Following the transaction, the insider now directly owns 36,959 shares of the company’s stock, valued at approximately $1,374,505.21. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 248,037 shares of company stock valued at $9,064,785. 0.06% of the stock is owned by corporate insiders.

PFE stock opened at $36.49 on Thursday. Pfizer has a twelve month low of $31.67 and a twelve month high of $39.43. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.35 and a quick ratio of 1.10. The company has a market cap of $217,458.14, a P/E ratio of 13.77, a P/E/G ratio of 1.83 and a beta of 0.90.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The company had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. During the same quarter last year, the company earned $0.47 EPS. The firm’s revenue for the quarter was up .6% on a year-over-year basis. equities research analysts forecast that Pfizer will post 2.95 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “MUFG Securities EMEA plc Raises Position in Pfizer (PFE)” was reported by Week Herald and is owned by of Week Herald. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://weekherald.com/2018/04/19/mufg-securities-emea-plc-raises-position-in-pfizer-pfe.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply